Email this article Association of gastric cancer main signaling pathway gene expression with metastasis
- Authors: Kipkeeva F.M.1, Muzaffarova Т.А.1, Nikulin M.P.2, Apanovich P.V.1, Nered S.N.2, Narimanov M.N.2, Malekhova O.A.2, Bogush Т.А.2, Stilidi I.S.2, Karpukhin A.V.1
-
Affiliations:
- Research Centre for Medical Genetics
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 17, No 4 (2018)
- Pages: 106-110
- Section: ORIGINAL REPORTS
- Published: 11.12.2018
- URL: https://bioterapevt.abvpress.ru/jour/article/view/1133
- DOI: https://doi.org/10.17650/1726-9784-2018-17-4-106-110
- ID: 1133
Cite item
Full Text
Abstract
Objective of the study. Identification of genes, the expression of which is associated with the metastasis of gastric cancer tumor.
Materials and methods. Quantitative real-time PCR on paired tumor – normal samples.
Results. An association with the metastasis of the VEGFR1, FGFR2 and NRP-1 gene expression is shown. The odds ratio (OR) was the highest for the FGFR2 gene: OR 175.00; 95 % CI 8.972–3413.271; for the VEGFR1 gene, OR 4.622, 95 % CI 1.240–17.227, for NRP1 – OR 2.667; 95 % CI 0.597–11.915. When assessing the jointly elevated expression of VEGFR1 and NRP1 genes, OR 5,778; 95 % CI 1.393–23.909; p = 0.0147. The frequency of increased expression of FGFR2 was 5 % in case of metastasis, while in the case of localized GC it reached 53 %.
Conclusion. The target drug against FGFR2, which is being developed, is likely to have a limited 5–10 % frequency of effective action in metastatic GC. Its use in the early stages of GC can help prevent the transition of the tumor to the metastatic stage. The possible interact tion of VEGFR1 and NRP1 will result in a small contribution to the metastasis of GC as compared to the effect of VEGFR1-only expression.Keywords
About the authors
F. M. Kipkeeva
Research Centre for Medical Genetics
Author for correspondence.
Email: Foty_k@mail.ru
ORCID iD: 0000-0003-4778-9726
1 Moskvorechie St., Moscow 115478 Russian Federation
Т. А. Muzaffarova
Research Centre for Medical Genetics
ORCID iD: 0000-0002-2345-2056
1 Moskvorechie St., Moscow 115478 Russian Federation
M. P. Nikulin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0002-9608-4696
24 Kashirskoe shosse, Moscow 115478 Russian Federation
P. V. Apanovich
Research Centre for Medical Genetics
ORCID iD: 0000-0001-6576-5512
1 Moskvorechie St., Moscow 115478 Russian Federation
S. N. Nered
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0002-5403-2396
24 Kashirskoe shosse, Moscow 115478 Russian Federation
M. N. Narimanov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0003-1806-8401
24 Kashirskoe shosse, Moscow 115478 Russian Federation
O. A. Malekhova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia24 Kashirskoe shosse, Moscow 115478 Russian Federation
Т. А. Bogush
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0002-7673-4284
24 Kashirskoe shosse, Moscow 115478 Russian Federation
I. S. Stilidi
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0002-5229-8203
24 Kashirskoe shosse, Moscow 115478
Russian FederationA. V. Karpukhin
Research Centre for Medical Genetics
ORCID iD: 0000-0002-7001-9116
1 Moskvorechie St., Moscow 115478 Russian Federation
References
Supplementary files
